Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
Soon after FDA approved generic versions of epinephrine injection USP (EpiPen, Mylan and Pfizer), a pharma maker is releasing a generic EpiPen for children.
Teva Pharmaceutical Industries said the FDA-approved version of EpiPen Jr. 0.15 mg is now available in most retail pharmacies. Teva’s generic version costs $300 per 2-pack.
Related: Epipen Shortage: Pharma Maker, Retailer Offer Aid
A year ago, FDA cleared the first generic version of epinephrine, granting Teva authority to make generic versions in 0.3 mg and 0.15 mg strengths.
“This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages.” said former FDA Commissioner Scott Gottlieb, MD, in a statement from FDA, at the time.
Related: Generic Epipen Poised To Alleviate Shortages
There is still a shortage of EpiPens in the U.S., Europe, and Canada. In fact, Pfizer and Mylan worked with FDA in June to extend the expiration dates by four months of all lots of EpiPen Auto-Injectors and its authorized generic version currently on the market in the US.
“Patients should have confidence in using the products as Pfizer works to stabilize supply,” Pfizer and Mylan said in a joint press release.
Meanwhile, Teva will continue working to ensure availability of both generic EpiPen strengths in the US and plan to accelerate production to meet the urgent need for this medicine,” said Brendan O’Grady, EVP and head of North America Commercial for Teva, in a statement.
Read more: FDA approves EpiPen rival
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More